Propafenone for paroxysmal atrial fibrillation

Stephen C. Hammill; Douglas L. Wood; Bernard J. Gersh; Michael J. Osborn; David R. Holmes

doi:10.1016/0002-9149(88)90312-8

Propafenone for paroxysmal atrial fibrillation

Stephen C. Hammill, Douglas L. Wood, Bernard J. Gersh, Michael J. Osborn, David R. Holmes

Research output: Contribution to journal › Article › peer-review

57 Scopus citations

Abstract

Propafenone is a class 1C antiarrhythmic agent potentially effective in paroxysmal atrial fibrillation (AF). Propafenone's effects upon automaticity and conduction in the atrium should decrease the frequency of AF. In the event of a recurrence of AF, its effects on atrioventricular nodal conduction would tend to slow the ventricular response.^1-3 Previously, we demonstrated that propafenone was safe and effective for treating patients with refractory complex ventricular ectopic activity⁴ and paroxysmal supraventricular reentrant tachycardia due to reentry in the atrioventricular node or by an accessory atrioventricular pathway.³ This study reviews our experience with propafenone in patients with paroxysmal AF who had long-term follow-up for control of their rhythm disturbance.

Original language	English (US)
Pages (from-to)	473-474
Number of pages	2
Journal	The American journal of cardiology
Volume	61
Issue number	6
DOIs	https://doi.org/10.1016/0002-9149(88)90312-8
State	Published - Feb 15 1988

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/0002-9149(88)90312-8

Cite this

@article{350f3b54986f45eba5e13266130623e8,

title = "Propafenone for paroxysmal atrial fibrillation",

abstract = "Propafenone is a class 1C antiarrhythmic agent potentially effective in paroxysmal atrial fibrillation (AF). Propafenone's effects upon automaticity and conduction in the atrium should decrease the frequency of AF. In the event of a recurrence of AF, its effects on atrioventricular nodal conduction would tend to slow the ventricular response.1-3 Previously, we demonstrated that propafenone was safe and effective for treating patients with refractory complex ventricular ectopic activity4 and paroxysmal supraventricular reentrant tachycardia due to reentry in the atrioventricular node or by an accessory atrioventricular pathway.3 This study reviews our experience with propafenone in patients with paroxysmal AF who had long-term follow-up for control of their rhythm disturbance.",

author = "Hammill, {Stephen C.} and Wood, {Douglas L.} and Gersh, {Bernard J.} and Osborn, {Michael J.} and Holmes, {David R.}",

year = "1988",

month = feb,

day = "15",

doi = "10.1016/0002-9149(88)90312-8",

language = "English (US)",

volume = "61",

pages = "473--474",

journal = "The American journal of cardiology",

issn = "0002-9149",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - Propafenone for paroxysmal atrial fibrillation

AU - Hammill, Stephen C.

AU - Wood, Douglas L.

AU - Gersh, Bernard J.

AU - Osborn, Michael J.

AU - Holmes, David R.

PY - 1988/2/15

Y1 - 1988/2/15

N2 - Propafenone is a class 1C antiarrhythmic agent potentially effective in paroxysmal atrial fibrillation (AF). Propafenone's effects upon automaticity and conduction in the atrium should decrease the frequency of AF. In the event of a recurrence of AF, its effects on atrioventricular nodal conduction would tend to slow the ventricular response.1-3 Previously, we demonstrated that propafenone was safe and effective for treating patients with refractory complex ventricular ectopic activity4 and paroxysmal supraventricular reentrant tachycardia due to reentry in the atrioventricular node or by an accessory atrioventricular pathway.3 This study reviews our experience with propafenone in patients with paroxysmal AF who had long-term follow-up for control of their rhythm disturbance.

AB - Propafenone is a class 1C antiarrhythmic agent potentially effective in paroxysmal atrial fibrillation (AF). Propafenone's effects upon automaticity and conduction in the atrium should decrease the frequency of AF. In the event of a recurrence of AF, its effects on atrioventricular nodal conduction would tend to slow the ventricular response.1-3 Previously, we demonstrated that propafenone was safe and effective for treating patients with refractory complex ventricular ectopic activity4 and paroxysmal supraventricular reentrant tachycardia due to reentry in the atrioventricular node or by an accessory atrioventricular pathway.3 This study reviews our experience with propafenone in patients with paroxysmal AF who had long-term follow-up for control of their rhythm disturbance.

UR - http://www.scopus.com/inward/record.url?scp=0024157394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024157394&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(88)90312-8

DO - 10.1016/0002-9149(88)90312-8

M3 - Article

C2 - 3341233

AN - SCOPUS:0024157394

SN - 0002-9149

VL - 61

SP - 473

EP - 474

JO - The American journal of cardiology

JF - The American journal of cardiology

IS - 6

ER -

Propafenone for paroxysmal atrial fibrillation

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this